Abu Dhabi, testing of the Chinese anti-Covid vaccine on minors is underway
About 900 children and young people between the ages of three and 17 are involved, including children and grandchildren of the royal family of Abu Dhabi. The goal is to start with a "mass vaccination campaign in the near future". In Dubai, about two-thirds of the adult population has already received both doses of the vaccine.
Abu Dhabi (AsiaNews / Agencies) - The United Arab Emirates (UAE) are currently launching a clinical trial for the use of the Chinese Sinopharm vaccine on children under 18. According to official media reports, the test involves a group of children and young people - boys and girls - between the ages of three and 17; among these there would also be some members of the royal family of Abu Dhabi, who wanted to join the initiative.
The trial phase intends to verify the immune response of at least 900 children and minors, in preparation for "a mass vaccination in the near future," the Abu Dhabi Media Office explained in a note released yesterday afternoon.
Local sources add that Sheikh Theyab bin Mohammed, son of the Crown Prince of Abu Dhabi and de facto leader of the country Sheikh Mohammed bin Zayed Al Nahyan, accompanied his children and grandchildren to the vaccination centre to join the clinical trials.
Last month the United Arab Emirates approved the Pfizer-BioNTech vaccine for emergency use in young people between the ages of 12 and 15, but that age has not yet fallen below that threshold. In June Dubai, the second most important member state of the federation, officially launched the immunization campaign while the other emirates have yet to begin.
The United Arab Emirates, one of the countries in the world with the highest immunization rate in relation to the population, yesterday recorded 2,011 new coronavirus infections, for a total of 603,961 cases and a total of 1738 deaths since the start of the health emergency. However, the health authorities do not provide the data on the infections spread over each of the seven emirates.
An estimated two thirds of the adult population in Dubai received both doses of the vaccine. In addition, the Gulf state has initiated "phase three" clinical trials of the vaccine manufactured by Sinopharm and has begun manufacturing it thanks to a joint venture between the Chinese pharmaceutical company and Group 42, a technology company based in Abu Dhabi.